Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) concluded the recent trading session at $17.13, signifying a +2.39% move from its prior day's close.
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
In the most recent trading session, Adma Biologics (ADMA) closed at $17.98, indicating a -3.75% shift from the previous trading day.
Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.
